June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

CTTQ, Akeso form JV to develop PD-1 mAb
The Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd. (HKEX:1177) formed a 50/50 joint venture with Akeso Biopharma Inc. (Zhongshan, China) to develop and commercialize Akeso’s AK105, an anti PD-1 mAb. CTTQ will contribute RMB344.7 million ($49.7 million) in

Read the full 516 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE